Expiring subsidies for Obamacare health premiums are part of the reason Democrats have refused to fund the federal government ...
in patients with malignant melanoma in the key phase 3 trials.4 5 This paved the way for the development and approval of other ICIs, beginning with monoclonal antibodies targeting programmed cell ...
Multitude Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of ADC drugs, today announced interim results from its ongoing Phase I/II open-label, multicenter ...
New research published in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, ...
Moderna has shared some of the phase 1/2 data that persuaded it to expand and p | Moderna has shared some of the phase 1/2 ...
The concept of adjuvant therapy for cancer was developed at a time when systemic cancer treatment was limited to cytotoxic chemotherapy that could only be administered intermittently but rarely ...
Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with ...
The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...
Select your location to view local American Lung Association events and news near you.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback